Journal of Vaccines & Vaccination

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

6^th Euro Global Summit and Expo on Vaccines & Vaccination

August 17-19, 2015 Birmingham, UK

K Kavanagh1, K G J Pollock2, A Potts2, J Love2, K Cuschieri3, H Cubie3, C Robertson1,2,4 and M Donaghy2

Posters-Accepted Abstracts: J Vaccines Vaccin

Abstract:

Background: In 2008, a national human papillomavirus (HPV) immunization programme began in Scotland for 12–13 year
olds females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent
vaccine in the routine cohort aged 12–13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%.
Methods: To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and post
introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By
linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunization
programme on circulating type-specific HPV infection particularly for four outcomes: (i) The vaccine types HPV 16 or 18
(ii) types considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV.
Results: From a total of 4679 samples tested, we demonstrated that three doses (n¼1100) of bivalent vaccine are associated
with a significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95%
confidence interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged
as the most prevalent (10.5% and 9.6%, respectively), non-vaccine high-risk types in those vaccinated but at lower rates than
HPV 16 (25.9%) in those unvaccinated.
Conclusions: This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45
in the target population and is encouraging for countries which have achieved high-vaccine uptake.